Fresenius SE & Co. (FSNUY) Projected to Post Earnings on Wednesday

Fresenius SE & Co. (OTCMKTS:FSNUY) is anticipated to post its results before the market opens on Wednesday, August 5th. Analysts expect Fresenius SE & Co. to post earnings of $0.25 per share and revenue of $6.6540 billion for the quarter.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.09% and a net margin of 6.55%.The firm had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $6.79 billion. On average, analysts expect Fresenius SE & Co. to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Fresenius SE & Co. Stock Performance

Shares of FSNUY stock opened at $12.88 on Monday. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $33.93. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. The firm has a market capitalization of $29.02 billion, a PE ratio of 17.17 and a beta of 0.63. The stock has a fifty day simple moving average of $11.63 and a two-hundred day simple moving average of $12.80.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.